Printed From:

Consistent Improvements in TNF-IR and MTX-IR Patients

Robust efficacy in patients with prior history of inadequate response1

Robust efficacy in patients with prior history of inadequate response1

Formats the Html codes.FormatFix the Html to be XHtml compliantFix Write Validate that the text is XHtml compliant.Validate Proofing

With KEVZARA 150 mg + DMARD (TARGET), 56% of patients achieved ACR20 response, 37% achieved ACR50 response, and 20%|| achieved ACR70 response week 24 (n=181)

With KEVZARA 150 mg + MTX (MOBILITY), 58% of patients achieved ACR20 response, 37% achieved ACR50 response, and 20% achieved ACR70 response at week 24 (n=400)

*After week 12 in TARGET and week 16 in MOBILITY, patients with an inadequate response could have been treated with open-label KEVZARA 200 mg every 2 weeks. P<0.0001; P<0.01; §DMARDs in TARGET include MTX, sulfasalazine, leflunomide, and/or hydroxychloroquine; ||P<0.001.

Reduction in Signs and Symptoms Were Observed Across all ACR Components (week 24)4
REDUCTION IN PAIN

REDUCTION IN PAIN

from baseline with
KEVZARA 200 mg + DMARD

compared to 39% reduction with
placebo + DMARD

REDUCTION IN TENDER AND SWOLLEN JOINTS

REDUCTION IN TENDER AND SWOLLEN JOINTS

from baseline with
KEVZARA 200 mg + DMARD

  • A 70% reduction in tender joints
    compared to 59% reduction with
    placebo + DMARD

  • A 73% reduction in swollen joints
    compared to 63% reduction with
    placebo + DMARD

REDUCTION IN MEDIAN CRP

REDUCTION IN MEDIAN CRP

levels from baseline with
KEVZARA 200 mg + DMARD

compared to 25% reduction with
placebo + DMARD

  • With KEVZARA 150 mg + DMARD, reduction from baseline was 69% in tender and 72% in swollen joints, 49% in pain, and 87% in median CRP

As early as 2 weeks after the first dose, KEVZARA normalized CRP levels (<10 mg/L) in patients with elevated CRP1,5

Sustained Efficacy in ACR50 and ACR70 (Week 52)1,3*
ACR50 RESPONSE

ACR50 RESPONSE

with KEVZARA 200 mg + MTX
compared to 18% response with
placebo + MTX

ACR70 RESPONSE

ACR70 RESPONSE

with KEVZARA 200 mg + MTX
compared to 9% response with
placebo + MTX

*P<0.0001, P value is for descriptive purposes only and is not adjusted for multiplicity.

Inhibit Progression of Joint Damage

Help control radiographic progression in your patients

KEVZARA 200 mg + MTX provided an absolute difference of 2.52 units (CI: -3.38, -1.66) in mean ΔmTSS relative to placebo + MTX

  • 68%* greater inhibition of joint damage progression with KEVZARA 150 mg + MTX at week 52 relative to placebo + MTX1

    • KEVZARA 150 mg + MTX provided an absolute difference of 1.88 units in mean mTSS relative to placebo + MTX

KEVZARA 200 mg + MTX significantly inhibited the progression of joint damage1

Week 52 analysis employs linear extrapolation method to impute missing or postrescue data.
*Based on post hoc comparisons of mean change in mTSS per treatment group.
CI=confidence interval.

Study Design

References: 1. KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc; 2. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277-290. 3. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424-1437. 4. Data on file, Sanofi/Regeneron. Integrated summary. April 1, 2017. 5. Center for Devices and Radiological Health. Guidance for industry and FDA staff: review criteria for assessment of c-reactive protein (CRP), high sensitivity c-reactive protein (hsCRP) and cardiac c-reactive protein (cCRP) assays. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm071017.pdf. Accessed October 18, 2017.